Bharat Biotech's Covaxin Shows Encouraging Results in Clinical Trials: Research Paper

Covaxin showed long-term antibody and T cell (immune) memory responses three months after the shot in phase 1 volunteers and tolerable safety outcomes in Phase 2 study, suggesting the antibodies may persist for six to 12 months.

from Top Business News- News18.com https://ift.tt/2KRn8SA